New York, NY -- (SBWIRE) -- 09/16/2013 -- StockMarketIntel.com issues a special report on the following stocks: Nanosphere, Inc. (NASDAQ:NSPH), Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), Galena Biopharma Inc (NASDAQ:GALE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR)
Nanosphere, Inc. (NASDAQ:NSPH) traded with volume of 3.52 million shares in the most recent session, as compared to average volume of 635,185 shares.
During the preceding trading session, the stock showed a bearish movement of -8.46%, to the closing price of $1.84. The one month performance graph illustrated it as a percentage loser of -10.24%. Nanosphere, Inc. develops, manufactures, and markets molecular diagnostics platform, the Verigene System that enables genomic and protein testing on a single platform.
Has NSPH Found The Bottom and Ready To Move Up? Find Out Here
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) in prior session, moved down -8.91% and, at the end of the day, closed the session at $4.50.
The stock traded with volume of 2.57 million shares in the last session, as compared to average volume of 831,580 shares. The market capitalization of the Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) was of 183.33 million. Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia.
Has PRAN Found The Bottom And Ready To Gain Momentum? Find Out Here
The stock which exchanged over 01 million shares in the preceding session was Galena Biopharma Inc (NASDAQ:GALE), as it traded with volume of 20.74 million shares and its average volume remained 1.62 million shares. The market capitalization of the stock remained $163.80 million. Yesterday, the stock dropped -14.91% and closed the session at $1.94. Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care.
Will GALE Get Buyers Even After The Recent Rally? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) remained with negative change of -18.24% and closed prior trading session at the price of $4.08. The stock changed hands vigorously in most recent session, as it traded 15.10 million shares, which was greater than average volume of 3.34 million shares. Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States.
Why Should Investors Buy AVNR After the Recent Fall? Just Go Here and Find Out
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.html
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)